Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine

Journal of Immunological Methods

Volumn 365, Issue 1-2, 2011, Pages 27-37

  Cobb, Amanda ^a,b   Roberts, Lee K ^c   Palucka, A Karolina ^a   Mead, Holly ^a   Montes, Monica ^a   Ranganathan, Rajaram ^a   Burkeholder, Susan ^a   Finholt, Jennifer P ^a   Blankenship, Derek ^a   King, Bryan ^d   Sloan, Louis ^d   Harrod, A Carson ^a,b   Lévy, Yves ^e,f,g   Banchereau, Jacques ^a  

^a BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^b BAYLOR UNIVERSITY   (United States)

^c Roberts Biotech Consulting   (United States)

^d North Texas Infectious Diseases Consultants   (United States)

^e INSERM U955   (France)

^f FACULTÉ DE MÉDECINE   (France)

^g HENRI MONDOR HOSPITAL   (France)

Author keywords

ANRS LIPO 5 vaccine; Antigen specific T cells; DC; HIV; IFN ; Vaccine development

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; CD14 ANTIGEN; CD1B ANTIGEN; CD1C ANTIGEN; CD83 ANTIGEN; CELL MARKER; DENDRITIC CELL VACCINE; GLYCOPROTEIN P 15095; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 13; LIPO 5 VACCINE; LIPOPOLYSACCHARIDE; UNCLASSIFIED DRUG;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOGENICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VACCINATION;

ADULT; AIDS VACCINES; AMINO ACID SEQUENCE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CELL DIFFERENTIATION; CHEMOKINES; COMBINED MODALITY THERAPY; CYTOKINES; DENDRITIC CELLS; EPITOPE MAPPING; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; LIPOPEPTIDES; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION, AUTOLOGOUS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79551582028     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2010.11.002     Document Type: Article

References (38)

1. Alvarez D., Vollmann E.H., von Andrian U.H. Mechanisms and consequences of dendritic cell migration. Immunity 2008, 29:325.
2. Appay V., Nixon D.F., Donahoe S.M., Gillespie G.M., Dong T., King A., Ogg G.S., Spiegel H.M., Conlon C., Spina C.A., Havlir D.V., Richman D.D., Waters A., Easterbrook P., McMichael A.J., Rowland-Jones S.L. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J. Exp. Med. 2000, 192:63.
3. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245.
4. Banchereau J., Ueno H., Dhodapkar M., Connolly J., Finholt J.P., Klechevsky E., Blanck J.P., Johnston D.A., Palucka A.K., Fay J. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34(+) progenitors and activated with type I interferon. J. Immunother. 2005, 28:505.
5. Bonaldo M.C., Martins M.A., Rudersdorf R., Mudd P.A., Sacha J.B., Piaskowski S.M., Neves P.C.C., de Santana M.G.V., Vojnov L., Capuano S., Rakasz E.G., Wilson N.A., Fulkerson J., Sadoff J.C., Watkins D.I., Galler R. Recombinant yellow fever vaccine virus 17D expressing simian immunodeficiency virus SIVmac239 Gag induces SIV-specific CD8(+) T-cell responses in Rhesus Macaques. J. Virol. 2010, 84:3699.
6. Borrow P., Lewicki H., Hanh B.H., Shaw G.M., Oldstone M.B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 1994, 68:6103.
7. Cao Y., Qin L., Zhang L., Safrit J., Ho D.D. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 1995, 332:201.
8. Carbonneil C., Aouba A., Burgard M., Cardinaud S., Rouzioux C., Langlade-Demoyen P., Weiss L. Dendritic cells generated in the presence of granulocyte-macrophage colony-stimulating factor and IFN-alpha are potent inducers of HIV-specific CD8 T cells. AIDS 2003, 17:1731.
9. Carcelain G., Tubiana R., Samri A., Calvez V., Delaugerre C., Agut H., Katlama C., Autran B. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection. J. Virol. 2001, 75:234.
10. Champagne P., Ogg G.S., King A.S., Knabenhans C., Ellefsen K., Nobile M., Appay V., Rizzardi G.P., Fleury S., Lipp M., Forster R., Rowland-Jones S., Sekaly R.P., McMichael A.J., Pantaleo G. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 2001, 410:106.
11. Connolly N.C., Whiteside T.L., Wilson C., Kondragunta V., Rinaldo C.R., Riddler S.A. Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-Infected individuals. Clin. Vaccine Immunol. 2008, 15:284.
12. Deeks S.G., Walker B.D. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007, 27:406.
13. Durier C., Launay O., Meiffredy V., Saidi Y., Salmon D., Levy Y., Guillet J.G., Pialoux G., Aboulker J.P. Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults. AIDS 2006, 20:1039.
14. Goepfert P.A., Bansal A., Edwards B.H., Ritter G.D., Tellez I., McPherson S.A., Sabbaj S., Mulligan M.J. A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon. J. Virol. 2000, 74:10249.
15. Goujard C., Marcellin F., Hendel-Chavez H., Burgard M., Meiffredy V., Venet A., Rouzioux C., Taoufik Y., El Habib R., Beumont-Mauviel M., Aboulker J.P., Levy Y., Delfraissy J.F., Grp P.-A.S. Interruption of antiretroviral therapy initiated during primary HIV-1 infection: Impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 randomized study. AIDS Res. Hum. Retroviruses 2007, 23:1105.
16. Hosmalin A., Andrieu M., Loing E., Desoutter J.F., Hanau D., Gras-Masse H., Dautry-Varsat A., Guillet J.G. Lipopeptide presentation pathway in dendritic cells. Immunol. Lett. 2001, 79:97.
17. Kaufmann G.R., Zaunders J.J., Cunningham P., Kelleher A.D., Grey P., Smith D., Carr A., Cooper D.A. Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection. AIDS 2000, 14:2643.
18. Koup R.A., Safrit J.T., Yunzhen C., Andrews C.A., McLeod G., Borkowsky W., Farthing C., Ho D.D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 1994, 68:4650.
19. Launay O., Durier C., Desaint C., Silbermann B., Jackson A., Pialoux G., Bonnet B., Poizot-Martin I., Gonzalez-Canali G., Cuzin L., Figuereido S., Surenaud M., Ben Hamouda N., Gahery H., Choppin J., Salmon D., Guerin C., Villada I.B., Guillet J.G., Grp A.V.S. Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial. PLoS ONE 2007, 2.
20. Levy Y., Gahery-Segard H., Durier C., Lascaux A.S., Goujard C., Meiffredy V., Rouzioux C., El Habib R., Beumont-Mauviel M., Guillet J.G., Delfraissy J.F., Aboulker J.P., Grp A.S. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS 2005, 19:279.
21. Liu J.Y., O'Brien K.L., Lynch D.M., Simmons N.L., La Porte A., Riggs A.M., Abbink P., Coffey R.T., Grandpre L.E., Seaman M.S., Landucci G., Forthal D.N., Montefiori D.C., Carville A., Mansfield K.G., Havenga M.J., Pau M.G., Goudsmit J., Barouch D.H. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009, 457:87.
22. Lu W., Arraes L.C., Ferreira W.T., Andrieu J.M. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med. 2004, 10:1359.
23. Martinon F., Grasmasse H., Boutillon C., Chirat F., Deprez B., Guillet J.G., Gomard E., Tartar A., Levy J.P. Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant-immune-response of Balb/C mice to human-immunodeficiency-virus envelope glycoprotein. J. Immunol. 1992, 149:3416.
24. McMichael A.J., Borrow P., Tomaras G.D., Goonetilleke N., Haynes B.F. The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. Immunol. 2010, 10:11.
25. Melief C.J.M. Cancer immunotherapy by dendritic cells. Immunity 2008, 29:372.
26. Palucka A.K., Ueno H., Fay J.W., Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol. Rev. 2007, 220:129.
27. Pialoux G., Gahery-Segard H., Sermet S., Poncelet H., Fournier S., Gerard L., Tartar A., Gras-Masse H., Levy J.P., Guillet J.G., Team A.V.S. Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers. AIDS 2001, 15:1239.
28. Pialoux G., Quercia R.P., Gahery H., Daniel N., Slama L., Girard P.M., Bonnard P., Rozenbaum W., Schneider V., Salmon D., Guillet J.G. Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA study. Clin. Vaccine Immunol. 2008, 15:562.
29. Rosenberg E.S., Billingsley J.M., Caliendo A.M., Boswell S.L., Sax P., Kalams S.A., Walker B.D. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997, 278:1447.
30. Routy J.P., Boulassel M.R., Yassine-Diab B., Nicolette C., Healey D., Jain R., Landry C., Yegorov O., Tcherepanova I., Monesmith T., Finke L., Sekaly R.P. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin. Immunol. 2010, 134:140.
31. Sabado R.L., Bhardwaj N. Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy-Uk 2010, 2:37.
32. Salmon-Ceron D., Durier C., Desaint C., Cuzin L., Surenaud M., Ben Hamouda N., Lelievre J.D., Bonnet B., Pialoux G., Poizot-Martin I., Aboulker J.P., Levy Y., Launay O., Grp A.V.T. Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial. AIDS 2010, 24:2211.
33. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419.
34. Timmerman J.M., Levy R. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. J. Immunol. 2000, 164:4797.
35. Vignali D.A.A., Collison L.W., Workman C.J. How regulatory T cells work. Nat. Rev. Immunol. 2008, 8:523.
36. Virgin H.W., Walker B.D. Immunology and the elusive AIDS vaccine. Nature 2010, 464:224.
37. Yu C.I., Gallegos M., Marches F., Zurawski G., Ramilo O., Garcia-Sastre A., Banchereau J., Palucka A.K. Broad influenza-specific CD8(+) T-cell responses in humanized mice vaccinated with influenza virus vaccines. Blood 2008, 112:3671.
38. Zhu X.M., Ramos T.V., Gras-Masse H., Kaplan B.E., BenMohamed L. Lipopeptide epitopes extended by an N-epsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity. Eur. J. Immunol. 2004, 34:3102.